Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study
2011

Cost-effectiveness of New Tuberculosis Vaccines in Zambia

Sample size: 468073 publication Evidence: moderate

Author Information

Author(s): Tseng Chia-Lin, Oxlade Olivia, Menzies Dick, Aspler Anne, Schwartzman Kevin

Primary Institution: McGill University

Hypothesis

Can novel vaccines for tuberculosis control be cost-effective compared to existing strategies in Zambia?

Conclusion

Investing in an improved TB vaccine is expected to lead to significant cost savings and a reduction in TB-related morbidity and mortality.

Supporting Evidence

  • A BCG replacement vaccine could prevent 932 TB cases and 422 deaths over 30 years.
  • The prime-boost strategy could avert 1,863 TB cases and 1,011 deaths.
  • Net savings of $3.6 million are expected with vaccination at birth alone.
  • Total costs for the prime-boost strategy are projected to be lower in the long run.

Takeaway

This study shows that a new TB vaccine could save money and help more people by preventing TB disease and deaths.

Methodology

A decision analysis model-based simulation was conducted from a societal perspective over a 30-year period.

Limitations

The analysis may underestimate costs and benefits due to the prorated attribution of initial vaccine development costs to Zambia.

Participant Demographics

The study focused on newborns in Zambia, a country with high HIV prevalence and TB incidence.

Digital Object Identifier (DOI)

10.1186/1471-2458-11-55

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication